Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its target price increased by Barclays from $15.00 to $17.00 in a report published on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other research analysts have also recently issued reports on TEVA. HSBC began coverage on shares of […]
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the transaction, the chief accounting officer now directly owns 10,676 […]
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.200-2.500 for the period, compared to the consensus estimate of 2.420. The company issued revenue guidance of $15.7 billion-$16.3 billion, compared to the consensus revenue estimate of $15.6 billion. Teva […]
Jump Financial LLC reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 16.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 218,799 shares of the company’s stock after selling 42,321 shares during the quarter. Jump Financial LLC’s holdings in Teva […]
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.200-2.500 for the period, compared to the consensus earnings per share estimate of 2.420. The company issued revenue guidance of $15.7 billion-$16.3 billion, compared to the consensus […]